title: Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.
abstract: Half the patients suffering from Graves' disease develop thyroid-associated orbitopathy (TAO). The severity of TAO varies considerably with a mild form characterized by dry eyes and discomfort to the severe form with sight-threatening exposure keratopathy and optic neuropathy. The pathogenesis and immunologic mechanisms underlying Graves' disease and TAO is unknown, however, advances toward this understanding have indicated a prominent role of orbital fibroblasts, T cells and B cells. These advances have led to novel strategies for clinical treatment using immunomodulatory modalities. Initial results included use of infliximab and etanercept (anti-TNF agents), but currently there is an increasing interest in anti-B cell (Rituximab) therapy. Rituximab has shown promising results in progressive, sight-threatening TAO. It has also shown encouraging results in halting or slowing the disease process in patients unresponsive to corticosteroids. The primary advantage of these immunomodulatory agents is based upon targeting the molecular mediators of the disease and avoiding the potential side effects of non-specific therapies.
authors: Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA.
authors: Rina
authors: R
authors: Bhatt
authors: Christine C
authors: CC
authors: Nelson
authors: Raymond S
authors: RS
authors: Douglas
keywords: Orbital fibroblasts; Rituximab; T and B cells; Thyroid-associated orbitopathy
references: J Immunol. 2003 Jun 15;170(12):6348-54
references: 12794168
references: Endocr Rev. 2003 Dec;24(6):802-35
references: 14671007
references: J Clin Endocrinol Metab. 2002 Jan;87(1):385-92
references: 11788681
references: N Engl J Med. 2009 Nov 26;361(22):2143-52
references: 19940299
references: Clin Exp Immunol. 2000 Sep;121(3):453-7
references: 10971510
references: Nat Immunol. 2002 Oct;3(10):944-50
references: 12244307
references: Nature. 1985 Apr 11-17;314(6011):537-9
references: 3157869
references: N Engl J Med. 1999 Jan 28;340(4):253-9
references: 9920948
references: Eur J Endocrinol. 2007 Jan;156(1):33-40
references: 17218723
references: Eye (Lond). 2005 Dec;19(12):1286-9
references: 15550932
references: Arthritis Rheum. 2009 Dec;60(12):3563-71
references: 19950291
references: J Clin Endocrinol Metab. 2003 May;88(5):1939-46
references: 12727937
references: J Clin Endocrinol Metab. 1994 May;78(5):1070-4
references: 8175962
references: Br J Ophthalmol. 2001 Oct;85(10):1220-4
references: 11567968
references: Thyroid. 2008 Sep;18(9):959-65
references: 18752427
references: Lancet. 1993 Oct 16;342(8877):949-54
references: 8105213
references: J Clin Endocrinol Metab. 2007 May;92(5):1769-72
references: 17284622
references: Invest Ophthalmol Vis Sci. 2009 May;50(5):2262-8
references: 19117935
references: J Immunol. 1999 Oct 15;163(8):4284-91
references: 10510367
references: Autoimmun Rev. 2006 Aug;5(7):437-42
references: 16920569
references: Blood. 1997 Sep 15;90(6):2188-95
references: 9310469
references: N Engl J Med. 2008 Feb 14;358(7):676-88
references: 18272891
references: Eye (Lond). 1997;11 ( Pt 5):717-22
references: 9474324
references: N Engl J Med. 1997 Jul 17;337(3):141-7
references: 9219699
references: Ophthalmology. 2008 Feb;115(2):398-409
references: 18082885
references: Orbit. 2005 Jun;24(2):117-9
references: 16191800
references: J Immunol. 1998 Aug 1;161(3):1163-8
references: 9686575
references: Thyroid. 2008 Dec;18(12):1291-6
references: 18976167
references: Thyroid. 1999 Mar;9(3):305-10
references: 10211609
references: Blood. 1994 Jan 15;83(2):435-45
references: 7506951
references: Br J Ophthalmol. 2003 Jun;87(6):773-6
references: 12770979
references: Diabetes. 2005 Jun;54(6):1763-9
references: 15919798
references: Crit Rev Oncol Hematol. 2001 Jan;37(1):13-25
references: 11164715
references: Ophthalmology. 2010 Jan;117(1):133-139.e2
references: 19818507
references: Ophthalmology. 2002 Dec;109(12):2342-6
references: 12466181
references: Eur J Endocrinol. 2008 Nov;159(5):609-15
references: 18628345
references: N Engl J Med. 2005 Jun 23;352(25):2598-608
references: 15972866
references: N Engl J Med. 2010 Feb 25;362(8):726-38
references: 20181974
references: Thyroid. 2006 Jul;16(7):709-10
references: 16889501
references: Immunol Lett. 2003 Jul 3;88(1):85-6
references: 12853167
references: Endocrinology. 2006 Oct;147(10):4559-60
references: 16980441
references: J Immunol. 1998 Oct 15;161(8):3912-8
references: 9780157
references: Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):377-92
references: 14561184
references: Exp Clin Endocrinol Diabetes. 1999;107 Suppl 5:S164-7
references: 10614913
references: Arthritis Rheum. 2010 Jan;62(1):171-8
references: 20039431
references: Am J Ophthalmol. 1995 Oct;120(4):511-7
references: 7573310
references: Eur J Endocrinol. 2006 Apr;154(4):511-7
references: 16556712
references: Klin Padiatr. 2008 Nov-Dec;220(6):342-7
references: 18949668
references: Ann Rheum Dis. 2002 Oct;61(10):883-8
references: 12228157
references: Clin Endocrinol (Oxf). 2010 Aug;73(2):149-52
references: 20148907
references: J Rheumatol Suppl. 2006 May;77:3-11
references: 16652439
references: Immunology. 1999 Jun;97(2):188-96
references: 10447731
references: Thyroid. 2002 Oct;12(10):855-60
references: 12487767
references: Eur J Immunol. 2002 Feb;32(2):477-85
references: 11813166
references: Endocr Rev. 1989 Aug;10(3):366-91
references: 2673756
references: Ophthalmology. 1984 Nov;91(11):1411-9
references: 6240008
references: Am J Pathol. 2003 Oct;163(4):1291-300
references: 14507638
references: J Exp Med. 1989 Oct 1;170(4):1463-8
references: 2677211